A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

September 10, 2021

Primary Completion Date

September 13, 2021

Study Completion Date

September 13, 2021

Conditions
Pneumococcal Infections
Interventions
BIOLOGICAL

Investigational 23-valent PPV

The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0·5 mL of sodium chloride, sodium dihydrogen phosphate and disodium hydrogen phosphate per injection

BIOLOGICAL

Control 23-valent PPV

The control vaccine was manufactured by Chengdu Institute of Biological products Co., Ltd. 25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0·5 mL of light disodium phenol phosphate, sodium hydrogen phosphate and sodium chloride per injection

Trial Locations (1)

475100

Kaifeng County Center for Disease Control and Prevention, Kaifeng

All Listed Sponsors
lead

Sinovac Biotech Co., Ltd

INDUSTRY

NCT04989465 - A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine | Biotech Hunter | Biotech Hunter